Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma

Tetsuhiro Kawata; Naoko Yamamoto; Kyoko Matsushita; Tomoko Naito; Hiroshi Ohtsuki; Makiko Takahashi

Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma

Tetsuhiro Kawata, Naoko Yamamoto, Kyoko Matsushita, Tomoko Naito, Hiroshi Ohtsuki, Makiko Takahashi

University Hospital

Research output: Contribution to journal › Article

Abstract

Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.

Original language	English
Pages (from-to)	1457-1460
Number of pages	4
Journal	Japanese Journal of Clinical Ophthalmology
Volume	63
Issue number	9
Publication status	Published - Sep 2009

ASJC Scopus subject areas

Ophthalmology

Access to Document

Fingerprint Dive into the research topics of 'Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma'. Together they form a unique fingerprint.

Cite this

@article{cee19259e0b44af78b892cc09d09f06b,

title = "Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma",

abstract = "Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.",

author = "Tetsuhiro Kawata and Naoko Yamamoto and Kyoko Matsushita and Tomoko Naito and Hiroshi Ohtsuki and Makiko Takahashi",

year = "2009",

month = sep,

language = "English",

volume = "63",

pages = "1457--1460",

journal = "Japanese Journal of Clinical Ophthalmology",

issn = "0370-5579",

publisher = "Igaku-Shoin Ltd",

number = "9",

}

TY - JOUR

T1 - Outcome of trabeculectomy with prior intravitreal bevacizumab injection for neovascular glaucoma

AU - Kawata, Tetsuhiro

AU - Yamamoto, Naoko

AU - Matsushita, Kyoko

AU - Naito, Tomoko

AU - Ohtsuki, Hiroshi

AU - Takahashi, Makiko

PY - 2009/9

Y1 - 2009/9

N2 - Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.

AB - Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.

UR - http://www.scopus.com/inward/record.url?scp=70350337763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350337763&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:70350337763

VL - 63

SP - 1457

EP - 1460

JO - Japanese Journal of Clinical Ophthalmology

JF - Japanese Journal of Clinical Ophthalmology

SN - 0370-5579

IS - 9

ER -